Related Experiment Videos
[Methods for studying vasodilator agents in arterial hypertension]
S Laurent1, R Asmar, B Pannier
1Laboratoire d'hemodynamique de l'hypertension artérielle, centre de diagnostic, hôpital Broussais, Paris.
Insights
Vasodilator therapy for hypertension needs to address more than just lowering blood pressure. Effective treatment should also focus on arterial structure, heart function, and blood flow to reduce cardiovascular risks.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hypertension Research
Context:
- The treatment of hypertension has historically focused on reducing mean arterial pressure.
- Large trials indicate that solely lowering blood pressure does not adequately reduce coronary morbidity and mortality.
- Existing antihypertensive agents may not fully reverse the complex hemodynamic and structural abnormalities in hypertensive disease.
Purpose:
- To re-evaluate the objectives of antihypertensive vasodilator therapy.
- To analyze the effects of major antihypertensive drug classes on key hemodynamic and structural parameters.
- To explore methods for studying vasodilators in the context of hypertension management.
Summary:
- Decreasing mean arterial pressure alone is insufficient for reducing hypertension-related coronary events.
- Effective vasodilator therapy should aim for regression of arterial structural changes and left ventricular hypertrophy (LVH).
- Therapeutic goals must include reduced blood pressure variability and preserved regional blood flow alongside pressure reduction.
Impact:
- This analysis provides a framework for optimizing antihypertensive vasodilator strategies.
- Highlights the need for a multifactorial approach in managing hypertensive cardiovascular risk.
- Informs the development of future antihypertensive drugs with improved efficacy in preventing cardiovascular complications.
Abstract:
The concept of vasodilatation has evolved with regards to the treatment of hypertension. Large multicentre trials have shown that decreasing mean arterial pressure alone does not reduce coronary morbidity and mortality related to hypertension. The authors suggest that the haemodynamic abnormalities related to hypertensive disease were not totally reversed by the antihypertensive agents used in these trials. Regression of structural arterial changes, regression of LVH without altering systolic function, reduction of the variability of blood pressure and maintenance of regional blood flow should all be objectives of any antihypertensive vasodilator therapy. Methods of studying vasodilators are described and the effects of the main classes of antihypertensive drugs on these parameters are analysed.